Identification of Patients Affected by Mitral Valve Prolapse with Severe Regurgitation: A Multivariable Regression Model
Table 1
Patient demographics.
Control
MVP
value
Variable
Age (years)
57.3 []
60.1 []
0.291
Sex (male)
19 (65.5%)
29 (67.4%)
0.865
Diabetes
3 (10.3%)
3 (7.0%)
0.685
Hypertension
14 (48.3%)
16 (37.2%)
0.660
Hypercholesterolemia
14 (48.3%)
25 (58.1%)
0.688
Smokers
6 (20.7%)
5 (11.6%)
0.514
BMI
0.005
Total cholesterol (mg/dL)
0.973
Triglycerides (mg/dL)
0.690
HDL (mg/dL)
0.249
LDL (mg/dL)
0.658
NYHA class
0.001
I
29 (100%)
19 (44.2%)
II
—
17 (39.5%)
III
—
7 (16.3)
IV
—
—
Drug therapies
Antiplatelets (%)
1 (3%)
2 (5%)
1.00
Angiotensin receptor blockers (%)
4 (14%)
3 (7%)
0.429
Converting enzyme inhibitors (%)
5 (17%)
14 (32%)
0.295
Calcium channel blockers (%)
3 (10%)
3 (7%)
0.679
Beta-blockers (%)
1 (3%)
16 (37%)
0.007
Nitrates (%)
0 (0%)
1 (2%)
1.00
Statins (%)
6 (21%)
6 (14%)
0.527
BMI: body mass index; HDL: high-density lipoprotein; LDL: low-density lipoprotein; NYHA: New York Heart Association. [minimum, maximum]; (percentage); mean ± standard error.
